CADILAHC:NSE-Cadila Healthcare Limited (INR)

COMMON STOCK | Pharmaceuticals | NSE

Last Closing Price

INR 339.15

Change

0.00 (0.00)%

Market Cap

INR 354.27B

Volume

1.00M

Avg Analyst Target

INR 486.50 (+43.45%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Cadila Healthcare Limited (CADILAHC) Stock Analysis:
Based on the Cadila Healthcare Limited stock forecasts from 4 analysts, the average analyst target price for Cadila Healthcare Limited is INR 486.50 over the next 12 months. Cadila Healthcare Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Cadila Healthcare Limited is Very Bullish, which is based on 19 positive signals and 0 negative signals. At the last closing, Cadila Healthcare Limited’s stock price was INR 339.15. Cadila Healthcare Limited’s stock price has changed by +0.00% over the past week, -6.20% over the past month and -44.69% over the last year.

About

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It offers finished dosage human formulations comprising generics, branded generics, and spec ...Read More

Company Website : https://www.zyduslife.com/zyduslife/

Address : Zydus Corporate Park, Ahmedabad, India, 382481

Employees : 24,412

Fiscal Year End : March

Currency: INR

Country : India

Technical Indicators

Beta : 0.64

52 Week High : 664.99

52 Week Low : 331.55

200 Day Moving Average : 504.70

50 Day Moving Average : 391.39

Shares Held By Insiders : 75.01%

Shares Held by Institutions : 14.91%

Dividend Yield : 1.01%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-21 )

Largest Industry Peers for Pharmaceuticals

ETFs Containing CADILAHC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Pharmaceuticals)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -29.80% 100% A+ 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.80% 100% A+ 14% F
Trailing 12 Months  
Capital Gain -44.69% 100% A+ 3% F
Dividend Return 0.57% 100% A+ 33% F
Total Return -44.12% 100% A+ 3% F
Trailing 5 Years  
Capital Gain -26.04% 100% A+ 34% F
Dividend Return 2.29% 100% A+ 31% F
Total Return -23.75% 100% A+ 33% F
Average Annual (5 Year Horizon)  
Capital Gain 9.46% 100% A+ 38% F
Dividend Return 0.64% 100% A+ 47% F
Total Return 10.10% 100% A+ 37% F
Risk Return Profile  
Volatility (Standard Deviation) 43.63% 100% A+ 65% D
Risk Adjusted Return 23.15% 100% A+ 40% F
Market Capitalization 354.27B 100% A+ 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Pharmaceuticals)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 7.43 100% A+ 84% B
Price/Book Ratio 2.25 100% A+ 47% F
Price / Cash Flow Ratio 10.76 100% A+ 45% F
EV/EBITDA 10.64 100% A+ 55% F
Management Effectiveness  
Return on Equity 15.40% 100% A+ 64% D
Return on Invested Capital 14.15% 100% A+ 79% C+
Return on Assets 6.71% 100% A+ 67% D+
Debt to Equity Ratio 4.69% 100% A+ 66% D
Technical Ratios  
Dividend Yield 1.01% 100% A+ 55% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.64 100% A+ 67% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:

There is nothing we particularly dislike